Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion

Allergan

Status: Completed

Conditions: Macular Edema; Retinal Vein Occlusion

Treatments: Drug: dexamethasone intravitreal implant

Study type: Observational

Funder types: Industry

Identifiers

NCT01618266

MAF/AGN/OPH/RET/009

Details and patient eligibility

About

Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.

Enrollment: 375 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Macular oedema due to retinal vein occlusion

Exclusion criteria

• Not living in metropolitan France

Trial design

375 participants in 1 patient group

Ozurdex® (dexamethasone intravitreal implant)

Description:

dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.

Treatment:

Drug: dexamethasone intravitreal implant